Genmab ASMEX:GMABN 92 Pretax Margin % is 8.26% as of Mar. 2026, which is 83% below its 10-year median of 47.22. GuruFocus rates MEX:GMABN with a GF Score™ of 92/100 and a GF Value™ of MXN5,328.99 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 946 Biotechnology companies, Genmab AS ranks better than 89.22% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Genmab AS's Pre-Tax Income for the
three
months ended in Mar. 2026 was MXN1,334 Mil. Genmab AS's Revenue for the
three
months ended in Mar. 2026 was MXN16,157 Mil. Therefore, Genmab AS's pretax margin for the quarter that ended in Mar. 2026 was 8.26%.
The historical rank and industry rank for Genmab AS's Pretax Margin % or its related term are showing as below:
MEX:GMABN'
s Pretax Margin % Range Over the Past 10 Years
Min: 26.5 Med: 47.22 Max: 62.23
Current: 26.5
MEX:GMABN's Pretax Margin % is ranked better than 89.22% of 946
companies
in the Biotechnology industry
Industry Median: -90.5
vs MEX:GMABN: 26.50
Genmab AS (MEX:GMABN) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Genmab AS Pretax Margin % Related Terms
Genmab AS Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Genmab AS's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:GMABN vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, Genmab AS's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genmab AS Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genmab AS's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Genmab AS's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genmab AS (MEX:GMABN) has a Pretax Margin % of 8.26% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Genmab AS and its competitors. This is 83% below median its historical median of 47.22. Over the past decade, Genmab AS's Pretax Margin % has ranged from 26.50 to 62.23. According to the industry distribution chart, Genmab AS ranks #102 out of 946 companies in the Biotechnology industry, placing it in the top 10.8%.
Is Genmab AS's Pretax Margin % too high?
Genmab AS's current Pretax Margin % of 8.26% is 83% below median its 10-year median of 47.22. Over the past 10 years, this metric has ranged from a low of 26.50 to a high of 62.23. Based on the distribution chart, Genmab AS ranks #102 out of 946 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Genmab AS has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genmab AS ranks #102 out of 946 companies for Pretax Margin %. This places Genmab AS in the top 11% of its industry — outperforming the majority of peers. Historically, Genmab AS's own Pretax Margin % has ranged from 26.50 to 62.23 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Genmab AS and its competitors. Genmab AS's current Pretax Margin % is 8.26%, which is 83% below median its own 10-year median of 47.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (MEX:GMABN) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN5,328.99, compared to a current price of MXN4,027.79 — trading 24.4% below its estimated fair value. The current Pretax Margin % is 8.26%, which is 83% below median its 10-year median of 47.22. Genmab AS's overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Genmab AS (MEX:GMABN), the current Pretax Margin % is 8.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genmab AS (MEX:GMABN) Overvalued in 2026?
Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued.
The current stock price of MXN4,027.79 is trading 24.4% below its estimated GF Value™ of MXN5,328.99.
GuruFocus considers Genmab AS to be Modestly Undervalued.
Key valuation signals for MEX:GMABN:
Pretax Margin %: 8.26% (83% below median its 10-year median of 47.22)
GF Value™: MXN5,328.99 vs. price of MXN4,027.79 (24.4% below fair value)
No single metric tells the full story. See the MEX:GMABN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
92GF Score
Get the complete analysis for MEX:GMABN
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:GMABN has been successfully added to your 
